MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.3 USD | -4.39% |
|
-6.15% | +17.96% |
| 05-10 | Equities Mostly Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey | MT |
| 05-10 | S&P 500, Dow Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey | MT |
| Sales 2024 * | 4.16B 332B | Sales 2025 * | 4.83B 386B | Capitalization | 44.96B 3,591B |
|---|---|---|---|---|---|
| Net income 2024 * | -2.71B -216B | Net income 2025 * | -1.96B -156B | EV / Sales 2024 * | 9.31 x |
| Net cash position 2024 * | 6.25B 499B | Net cash position 2025 * | 3.94B 315B | EV / Sales 2025 * | 8.49 x |
| P/E ratio 2024 * |
-16.6
x | P/E ratio 2025 * |
-22.8
x | Employees | 5,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | -4.39% | ||
| 1 week | -6.15% | ||
| Current month | +6.35% | ||
| 1 month | +9.49% | ||
| 3 months | +34.21% | ||
| 6 months | +67.47% | ||
| Current year | +17.96% |
1 week
116.73
125.50
1 month
99.30128.81
Current year
84.06128.81
1 year
62.55142.79
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 28/02/11 |
James Mock
DFI | Director of Finance/CFO | 47 | 05/09/22 |
Stephen Hoge
PSD | President | 48 | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 31/05/18 |
| Director/Board Member | 74 | 30/06/20 | |
Francois Nader
BRD | Director/Board Member | 67 | 10/12/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 117.3 | -4.39% | 4,238,508 |
| 09/05/24 | 122.7 | +0.66% | 3,367,379 |
| 08/05/24 | 121.9 | +0.68% | 2,507,503 |
| 07/05/24 | 121.1 | -0.87% | 2,894,011 |
| 06/05/24 | 122.1 | -2.30% | 3,953,207 |
Delayed Quote Nasdaq, May 10, 2024 at 09:00 pm
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B | |
| +20.18% | 11.72B |
- Stock Market
- Equities
- MRNA Stock
